Biotech & Life Sciences

A federal vaccine adviser who spent years on the front lines of CDC immunization policy has stepped down, adding another layer of instability to an agency already operating under a court injunction and a Thursday deadline to name a permanent director. The adviser, infectious disease specialist Dr.

A cluster of neurons smaller than a pea has learned to balance a pole. Not metaphorically.

Glioblastoma kills most of its victims within 18 months of diagnosis.

Pharmaceutical companies caught paying doctors to prescribe their drugs have paid roughly two cents in penalties for every dollar of revenue generated by the drugs involved in those schemes over the past quarter century.

Patrick Soon-Shiong has spent a decade in the spotlight, promising to upend cancer care with a sprawling empire of biotech companies.

Two biotech companies — Karyopharm and Rezolute — two very different stumbles toward the same regulator, and an FDA that may be rewriting the rulebook on what counts as enough evidence to approve a drug. Karyopharm Therapeutics on Monday reported topline results from the Phase 3 SENTRY trial of ...

Doctronic’s new funding round matters less as a startup vanity metric than as a test of whether medicine will let software cross one of its oldest lines: writing the prescription.

President Donald Trump’s most-favored-nation drug pricing push appears to have a problem baked into its design: by the administration’s own telling, the deals are structured less to force down U.S.

Gilead Sciences, the Foster City drugmaker best known for antivirals and now pushing deeper into inflammation, is paying a startling amount for Ouro Medicines, a young autoimmune biotech.

Merck is not making a single inflammatory bowel disease bet.

For 15 years, the dominant strategy for curing HIV has been shock-and-kill: flush the virus out of the cells where it hides, then destroy it.